The title of this proceedings comes from the book The Antibiotic Paradox by Stuart B. Levy (Plenum Publishing Corporation, 1992), referring to the paradox that the more antibiotics are used to treat infectious diseases, the less effective they become. When antibiotics were first introduced, they were considered wonder drugs because they were so effective. But with time bacteria have become resistant to nearly all antibiotics, and resistance is spreading faster than new antibiotics are being developed. This book will identify the issues concerning resistance, as well as describe efforts to develop new drugs that overcome the problem of resistance.…mehr
The title of this proceedings comes from the book The Antibiotic Paradox by Stuart B. Levy (Plenum Publishing Corporation, 1992), referring to the paradox that the more antibiotics are used to treat infectious diseases, the less effective they become. When antibiotics were first introduced, they were considered wonder drugs because they were so effective. But with time bacteria have become resistant to nearly all antibiotics, and resistance is spreading faster than new antibiotics are being developed. This book will identify the issues concerning resistance, as well as describe efforts to develop new drugs that overcome the problem of resistance.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1. Antibiotic Resistance: The Big Picture; D. Mazel, J. Davies. 2. Clinical impact of Antibiotic Resistance; S.A. Lerner. 3. Reversing Tetracycline Resistance: A Renaissance for the Tetracycline Family of Antibiotics; S.B. Levy, M. Nelson. 4. Aminoglycoside Antibiotics: Structures, Functions, and Resistance; G.D. Wright, et al. 5. How beta-Lactamases have Driven Pharmaceutical Drug Discovery; From Mechanistic Knowledge to Clinical Circumvention; K. Bush, S. Mobashery. 6. Antifolate Resistance Mechanisms from Bacteria to Cancer Cells with Emphasis on Parasites; M. Ouellette, et al. 7. Resistance to Antitubercular Drugs; L.A. Basso, J.S. Blanchard. 8. Structure and Function of Multidrug Transporters; H.W. van Veen, W.N. Konings. 9. Metalloid Resistance Mechanisms; R. Mukhopadhyay, et al. 10. The Impact of Bacterial Genomics on Antibacterial Discovery; D.J.C. Knowles, F. King. 11. Peptidoglycan Biosynthesis: Unexploited Antibacterial Targets within a Familiar Pathway; K.K. Wong, D.L. Pompliano. 12. Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active against Multidrug-Resistant Bacteria; M.R. Barbachyn, et al. 13. Concept, Design, and Preclinical Evaluation of Quinolonyl Lactam Antibacterials; P.M. Hershberger, T.P. Demuth Jr. 14. Bacterial Two-Component Signalling as a Therapeutic Target in Drug Design: Inhibition of NRII by the Diphenolic Methanes (Bisphenols); J.M. Domagala, et al. Index.
1. Antibiotic Resistance: The Big Picture; D. Mazel, J. Davies. 2. Clinical impact of Antibiotic Resistance; S.A. Lerner. 3. Reversing Tetracycline Resistance: A Renaissance for the Tetracycline Family of Antibiotics; S.B. Levy, M. Nelson. 4. Aminoglycoside Antibiotics: Structures, Functions, and Resistance; G.D. Wright, et al. 5. How beta-Lactamases have Driven Pharmaceutical Drug Discovery; From Mechanistic Knowledge to Clinical Circumvention; K. Bush, S. Mobashery. 6. Antifolate Resistance Mechanisms from Bacteria to Cancer Cells with Emphasis on Parasites; M. Ouellette, et al. 7. Resistance to Antitubercular Drugs; L.A. Basso, J.S. Blanchard. 8. Structure and Function of Multidrug Transporters; H.W. van Veen, W.N. Konings. 9. Metalloid Resistance Mechanisms; R. Mukhopadhyay, et al. 10. The Impact of Bacterial Genomics on Antibacterial Discovery; D.J.C. Knowles, F. King. 11. Peptidoglycan Biosynthesis: Unexploited Antibacterial Targets within a Familiar Pathway; K.K. Wong, D.L. Pompliano. 12. Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active against Multidrug-Resistant Bacteria; M.R. Barbachyn, et al. 13. Concept, Design, and Preclinical Evaluation of Quinolonyl Lactam Antibacterials; P.M. Hershberger, T.P. Demuth Jr. 14. Bacterial Two-Component Signalling as a Therapeutic Target in Drug Design: Inhibition of NRII by the Diphenolic Methanes (Bisphenols); J.M. Domagala, et al. Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826